Thibault DESMAREST

Bio

After studying medical biology at the Université Pierre et Marie Curie in Paris, Thibault Desmarest went on to study business at the EDHEC Group in Lille and then at Harvard Business School in Boston (USA) in 2013. He began his career in 1997 at Synthélabo France as Medical Representative, then Product Manager, before joining AstraZeneca France in 2000, where he held various sales positions of increasing responsibility in connection with product launches in respiratory and cardiology. In 2006, he became Director of Sales Network Excellence at Sanofi's global headquarters in Paris, then moved to the United States as Director of Sales & Marketing Excellence for the US subsidiary, before taking on responsibilities for Strategy & Business Excellence at the Global Oncology Division based in Boston. He left the US in 2012 to move to Japan, where he initially held marketing responsibilities at national level, before being appointed General Manager for a wider geographical area, including Japan, Australia, New Zealand and Korea. Returning to the global headquarters in Paris, from 2016 he was responsible for launching an innovative biotherapy in around thirty countries as Global Brand Leader, before being appointed Vice President in charge of the Northern Europe Region in 2020. These international experiences within a major French company have enabled him to promote French pharmaceutical excellence throughout the world. In February 2022, he was appointed President of GSK France, a leading international biopharmaceutical company in France, in terms of presence and industrial footprint, with 3,400 employees spread over 4 sites: the headquarters in Rueil-Malmaison (Greater Paris) and 3 production sites located in Évreux (Normandy - inhaled respiratory treatments), Mayenne (Pays de la Loire region - antibiotics) and Saint-Amand-les-Eaux (Northern France - vaccines). In this position for the past two years, Thibault Desmarest has worked to raise the profile of the French subsidiary within the British-based GSK group. Thanks to his commitment, at the last Choose France summit, the GSK laboratory announced €600 million of investment between 2024 and 2026 in France, in R&D as well as for the three production sites. Since 2021, Thibault Desmarest has also been a volunteer with the OSER 75 association (a non-profit organisation created in 2014). The OSER 75 association helps executives looking for work to regain their confidence so that they can respond appropriately to market expectations. This association values benevolence, personal investment and team spirit.